Table 2.
Demographic characteristics and outcomes of kidney transplant patients who developed acute rejection following immune checkpoint inhibitors
| Variable | Total (N = 18) |
|---|---|
| Age, yr | 62 ± 13 |
| Male sex | 15 (83) |
| Immune checkpoint inhibitor, n (%) | |
| - Nivolumab | 8 (44) |
| - Pembrolizumab | 3 (17) |
| - Ipilimumab | 2 (11) |
| - Ipilimumab followed by pembrolizumab | 2 (11) |
| - Ipilimumab followed by nivolumab | 2 (11) |
| - Pembrolizumab followed by nivolumab | 1 (6) |
| Cancer | |
| - Melanoma | 12 (67) |
| - Lung cancer | 3 (17) |
| - Metastatic squamous cell carcinoma of skin | 3 (17) |
| Time from immune checkpoint treatment to rejection, d | 24 (10–60) |
| Type of rejection | |
| - Acute cellular rejection | 6 (33) |
| - Acute mixed rejection | 3 (17) |
| - Unspecified | 9 (50) |
| Graft failure | 15 (83) |
| Cancer outcomes | |
| - Complete response | 1 (6) |
| - Partial response | 3 (17) |
| - Stable disease | 5 (28) |
| - Progressive disease | 7 (39) |
| - Not available | 2 (11) |
| Death | 8 (44) |